Changes of proportion of RRMS patients with Cognitive Impairment (CI) after 1–2 year Natalizumab treatment.

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Kerbrat, A.
Le Page, E.
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, D.
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

September 2011

International audienceBackground: In order to reduce the risk of progressive multifocal leucoencepha...

On-treatment inflammatory disease activity does not affect overall disability survival analysis.

Joel Raffel (3148509)
Arie R. Gafson (3636262)
Samer Dahdaleh (238230)
Omar Malik (2621161)
Brynmor Jones (3636259)
Richard Nicholas (790649)

January 2017

First year after natalizumab initiation Modified Rio Score (A), relapses (B), and MRI activity (C...

Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.

Lanzillo R
BONAVITA, Simona
Quarantelli M
Vacca G
LUS, Giacomo
Amato L
Carotenuto A
TEDESCHI, Gioacchino
Orefice G
Brescia Morra V.

January 2013

Natalizumab is one option for multiple sclerosis patients responding poorly to classical immunomodul...

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)

Wiendl Heinz
Butzkueven Helmut
Kappos Ludwig
Trojano Maria
Pellegrini Fabio
Paes Dominic
Zhang Annie
Belachew Shibeshih

January 2016

To evaluate the effect of natalizumab on disability progression beyond 2 years of treatment in clini...

Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP)

Wiendl, Heinz
Butzkueven, Helmut
Kappos, Ludwig
Trojano, Maria
Pellegrini, Fabio
Paes, Dominic
Zhang, Annie
Belachew, Shibeshih

January 2016

Objective To evaluate the effect of natalizumab on disability progression beyond 2 years of treatmen...

Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients

IAFFALDANO, PIETRO
Viterbo, Rosa Gemma
TROIANO, Maria

January 2016

Natalizumab discontinuation is associated with a disease reactivation in multiple sclerosis (MS) pat...

Number of patients who cognitively deteriorated, remained stable or improved after the intervention, separately displayed according to the incidence of new DWI lesions.

Laura Tiemann (326797)
Jutta Hubertina Reidt (370599)
Lorena Esposito (370600)
Dirk Sander (115239)
Wolfram Theiss (370601)
Holger Poppert (115238)

February 2013

Number of patients who cognitively deteriorated, remained stable or improved after the interventi...

Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies

Kathrin S. Utz
De-Hyung Lee
Alexandra Lämmer
Anne Waschbisch
Ralf A. Linker
Thomas Schenk

July 2016

Objectives: Disease-modifying therapies (DMTs) are applied to delay or prevent disease progression i...

Natalizumab significantly improves cognitive impairment over three years in MS: Pattern of disability progression and preliminary MRI Findings

Mattioli F.
Stampatori C.
Bellomi F.
Scarpazza C.
Capra R.

January 2015

Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or ...

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing remitting multiple sclerosis included in the randomized clinical trials of Natalizumab or Fingolimod.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Dimitris Mavridis (3184881)
Nikolaos Grigoriadis (261798)
Efthymios Dardiotis (3184878)
Ioannis Heliopoulos (700375)
Panagiotis Papathanasopoulos (789573)
Theodoros Karapanayiotides (3184875)
Constantinos Kilidireas (700376)
Georgios M. Hadjigeorgiou (342829)
Konstantinos Voumvourakis (700377)

September 2016

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing...

Proportion of RRMS patients with not evidence of disease activity (NEDA) under treatment with RTX (red) and NTZ (blue) over 30 months follow up.

Barbara Scotti (5216084)
Giulio Disanto (125817)
Rosaria Sacco (5216087)
Marilu’ Guigli (5216081)
Chiara Zecca (2586769)
Claudio Gobbi (2586757)

May 2018

Proportion of RRMS patients with not evidence of disease activity (NEDA) under treatment with RTX...

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study

Iaffaldano Pietro
Viterbo Rosa Gemma
Paolicelli Damiano
Lucchese Guglielmo
Portaccio Emilio
Goretti Benedetta
Direnzo Vita
D'Onghia Mariangela
Zoccolella Stefano
Amato Maria Pia
Trojano Maria

April 2012

Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relaps...

Cognitive functioning following one-year natalizumab treatment : A non-randomized clinical trial

Rorsman, I.
Petersen, C
Nilsson, P.C.

January 2018

Objectives: Cognitive impairment is common in multiple sclerosis (MS) and can have serious impact on...

Natalizumab: a country-based surveillance program

MANCARDI GL
AMATO MP
D'ALESSANDRO R
DRAGO F
MILANESE C
POPOLI P
PROVINCIALI L
ROSSI P
SAVETTIERI, Giovanni
TEDESCHI G
TOLA MR
VANACORE N
COVEZZOLI A
De Rosa, Maria Rosaria
PICCINNI C
MONTANARO N
PERIOTTO L
ADDIS A
MARTINI N.

January 2008

Natalizumab is a humanized monoclonal antibody with a selective adhesion-molecule inhibitor effect, ...

Percentage of T25FW responders over shorter-term (6–8 months) and longer-term (24–30 months) follow-up in disabled RRMSa and SPMS subjects during treatment with natalizumab compared with placebo or IM IFNβ-1a.

Diego Cadavid (105922)
Stephanie Jurgensen (105928)
Sophia Lee (105932)

January 2013

aDisabled RRMS subjects defined as those with EDSS ≥3.5 and T25FW >5 seconds at baseline.b...

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Kerbrat, A.
Le Page, E.
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, D.
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

September 2011

International audienceBackground: In order to reduce the risk of progressive multifocal leucoencepha...

On-treatment inflammatory disease activity does not affect overall disability survival analysis.

Joel Raffel (3148509)
Arie R. Gafson (3636262)
Samer Dahdaleh (238230)
Omar Malik (2621161)
Brynmor Jones (3636259)
Richard Nicholas (790649)

January 2017

First year after natalizumab initiation Modified Rio Score (A), relapses (B), and MRI activity (C...

Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.

Lanzillo R
BONAVITA, Simona
Quarantelli M
Vacca G
LUS, Giacomo
Amato L
Carotenuto A
TEDESCHI, Gioacchino
Orefice G
Brescia Morra V.

January 2013

Natalizumab is one option for multiple sclerosis patients responding poorly to classical immunomodul...

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)

Wiendl Heinz
Butzkueven Helmut
Kappos Ludwig
Trojano Maria
Pellegrini Fabio
Paes Dominic
Zhang Annie
Belachew Shibeshih

January 2016

To evaluate the effect of natalizumab on disability progression beyond 2 years of treatment in clini...

Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP)

Wiendl, Heinz
Butzkueven, Helmut
Kappos, Ludwig
Trojano, Maria
Pellegrini, Fabio
Paes, Dominic
Zhang, Annie
Belachew, Shibeshih

January 2016

Objective To evaluate the effect of natalizumab on disability progression beyond 2 years of treatmen...

Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients

IAFFALDANO, PIETRO
Viterbo, Rosa Gemma
TROIANO, Maria

January 2016

Natalizumab discontinuation is associated with a disease reactivation in multiple sclerosis (MS) pat...

Number of patients who cognitively deteriorated, remained stable or improved after the intervention, separately displayed according to the incidence of new DWI lesions.

Laura Tiemann (326797)
Jutta Hubertina Reidt (370599)
Lorena Esposito (370600)
Dirk Sander (115239)
Wolfram Theiss (370601)
Holger Poppert (115238)

February 2013

Number of patients who cognitively deteriorated, remained stable or improved after the interventi...

Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies

Kathrin S. Utz
De-Hyung Lee
Alexandra Lämmer
Anne Waschbisch
Ralf A. Linker
Thomas Schenk

July 2016

Objectives: Disease-modifying therapies (DMTs) are applied to delay or prevent disease progression i...

Natalizumab significantly improves cognitive impairment over three years in MS: Pattern of disability progression and preliminary MRI Findings

Mattioli F.
Stampatori C.
Bellomi F.
Scarpazza C.
Capra R.

January 2015

Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or ...

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing remitting multiple sclerosis included in the randomized clinical trials of Natalizumab or Fingolimod.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Dimitris Mavridis (3184881)
Nikolaos Grigoriadis (261798)
Efthymios Dardiotis (3184878)
Ioannis Heliopoulos (700375)
Panagiotis Papathanasopoulos (789573)
Theodoros Karapanayiotides (3184875)
Constantinos Kilidireas (700376)
Georgios M. Hadjigeorgiou (342829)
Konstantinos Voumvourakis (700377)

September 2016

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing...

Proportion of RRMS patients with not evidence of disease activity (NEDA) under treatment with RTX (red) and NTZ (blue) over 30 months follow up.

Barbara Scotti (5216084)
Giulio Disanto (125817)
Rosaria Sacco (5216087)
Marilu’ Guigli (5216081)
Chiara Zecca (2586769)
Claudio Gobbi (2586757)

May 2018

Proportion of RRMS patients with not evidence of disease activity (NEDA) under treatment with RTX...

Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study

Iaffaldano Pietro
Viterbo Rosa Gemma
Paolicelli Damiano
Lucchese Guglielmo
Portaccio Emilio
Goretti Benedetta
Direnzo Vita
D'Onghia Mariangela
Zoccolella Stefano
Amato Maria Pia
Trojano Maria

April 2012

Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relaps...

Cognitive functioning following one-year natalizumab treatment : A non-randomized clinical trial

Rorsman, I.
Petersen, C
Nilsson, P.C.

January 2018

Objectives: Cognitive impairment is common in multiple sclerosis (MS) and can have serious impact on...

Natalizumab: a country-based surveillance program

MANCARDI GL
AMATO MP
D'ALESSANDRO R
DRAGO F
MILANESE C
POPOLI P
PROVINCIALI L
ROSSI P
SAVETTIERI, Giovanni
TEDESCHI G
TOLA MR
VANACORE N
COVEZZOLI A
De Rosa, Maria Rosaria
PICCINNI C
MONTANARO N
PERIOTTO L
ADDIS A
MARTINI N.

January 2008

Natalizumab is a humanized monoclonal antibody with a selective adhesion-molecule inhibitor effect, ...

Percentage of T25FW responders over shorter-term (6–8 months) and longer-term (24–30 months) follow-up in disabled RRMSa and SPMS subjects during treatment with natalizumab compared with placebo or IM IFNβ-1a.

Diego Cadavid (105922)
Stephanie Jurgensen (105928)
Sophia Lee (105932)

January 2013

aDisabled RRMS subjects defined as those with EDSS ≥3.5 and T25FW >5 seconds at baseline.b...

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

Kerbrat, A.
Le Page, E.
Leray, Emmanuelle
Anani, T.
Coustans, M.
Desormeaux, C.
Guiziou, C.
Kassiotis, P.
Lallement, F.
Laplaud, D.
Diraison, P.
Rouhart, F.
Sartori, E.
Wardi, R.
Wiertlewski, S.
Edan, Gilles

September 2011

International audienceBackground: In order to reduce the risk of progressive multifocal leucoencepha...

On-treatment inflammatory disease activity does not affect overall disability survival analysis.

Joel Raffel (3148509)
Arie R. Gafson (3636262)
Samer Dahdaleh (238230)
Omar Malik (2621161)
Brynmor Jones (3636259)
Richard Nicholas (790649)

January 2017

First year after natalizumab initiation Modified Rio Score (A), relapses (B), and MRI activity (C...

Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.

Lanzillo R
BONAVITA, Simona
Quarantelli M
Vacca G
LUS, Giacomo
Amato L
Carotenuto A
TEDESCHI, Gioacchino
Orefice G
Brescia Morra V.

January 2013

Natalizumab is one option for multiple sclerosis patients responding poorly to classical immunomodul...

Changes of proportion of RRMS patients with Cognitive Impairment (CI) after 1–2 year Natalizumab treatment.

Abstract

Extracted data

Changes of proportion of RRMS patients with Cognitive Impairment (CI) after 1–2 year Natalizumab treatment.

Abstract

Extracted data

Related items

Related items